Sancilio, Amelia E.
D’Aquila, Richard T.
McNally, Elizabeth M.
Velez, Matthew P.
Ison, Michael G.
Demonbreun, Alexis R.
McDade, Thomas W.
Funding for this research was provided by:
National Science Foundation (2035114)
National Institutes of Health (UL1TR001422)
Article History
Received: 10 February 2021
Accepted: 8 July 2021
First Online: 28 July 2021
Competing interests
: Dr. McDade reports that he has a financial interest in EnMed Microanalytics, a company that conducts lab tests using DBS samples. Dr. D'Aquila reports personal fees from Abbvie, outside the submitted work. Dr. McNally reports personal fees from Amgen, personal fees from AstraZeneca, personal fees from Cytokinetics, personal fees from Pfizer, personal fees from Tenaya Therapeutics, personal fees from 4D Molecular Therapeutics, outside the submitted work. The remaining authors declare no additional competing interests.